Hypoglycemic Activity of Glyburide (Glibenclamide) Metabolites in Humans
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To assess the hypoglycemie effect and the insulin-releasing effect of the main glyburide (glibenclamide) metabolites 4-trans-hydroxy-glibenclamide (Ml) and 3-cis-hydroxy-glibenclamide (M2) in humans. RESEARCH DESIGN AND METHODS: Eight healthy subjects participated in a placebo-controlled, randomized, single-blind crossover study with five single-dose tests, 3 months apart: 3.5 mg glibenclamide (Gb) orally, 3.5 mg Gb intravenously, 3.5 mg Ml intravenously, 3.5 mg M2 intravenously, and placebo intravenously, each in the fasting state. Standardized meals were given 0.5 and 5.5 h after each medication. Blood glucose levels were measured by a glucose oxidase method, and serum insulin concentrations were analyzed by a specific immunoassay. RESULTS: Blood glucose levels during the first 5 h were significantly lowered not only by Gb but also by Ml and M2. The mean ± SE blood glucose reductions (versus placebo) expressed as percent of area under the curve (AUC) (0-5 h) were 18.2 ± 3.3% for Ml, 12.5 ± 2.3% forM2,19.9 ± 2.1% for intravenous Gb, and 23.8 ± 1.2% for Gb orally. Serum insulin levels were significantly increased by Gb as well as by Ml and M2. CONCLUSIONS: The two main metabolites of glyburide (glibenclamide) have a hypoglycémie effect in humans, which is due to increased insulin secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
“Glyburide is extensively metabolized in the liver into several activemetabolites that are excreted by the kidney and is not recommended for use in CKD (73,88).”
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 890
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
State of the art paper Sulfonylureas and their use in clinical practice
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Fra, G. P., Bartoli, E., & Derosa, G. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.53304 · Cited by 514
“The biological effect of sulfonylureas often lasts much longer than their plasma half-life, because of receptor interaction and formation of active metabolites [19, 20], persisting 24 h or more.”
BackgroundSavic, R. M., Jonker, D. M., Kerbusch, T., & Karlsson, M. O. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9066-0 · Cited by 500
Metadata
- Authors
- Rydberg, T., Jönsson, A., Røder, M., & Melander, A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1994-09-01
- Volume
- 17
- Issue
- 9
- Pages
- 1026-1030
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1969535782
- Cited by
- 112
- References
- 0
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypoglycemic Activity of Glyburide (Glibenclamide) Metabolites in Humans. https://app.cochat.ai/papers/10.2337/diacare.17.9.1026
- The paper
- Rydberg, T., Jönsson, A., Røder, M., & Melander, A. (1994). Hypoglycemic Activity of Glyburide (Glibenclamide) Metabolites in Humans. Diabetes Care. https://doi.org/10.2337/diacare.17.9.1026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.